|  | 
| Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma. | 
|  | 
|  | 
| Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda | 
| Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda | 
| Research Funding - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda | 
|  | 
| Ana María  Arance Fernández | 
| No Relationships to Disclose | 
|  | 
|  | 
| Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Roche/Genentech | 
|  | 
|  | 
| Honoraria - Bristol-Myers Squibb; Eisai; GlaxoSmithKline; MSD; Novartis; Pfizer; Roche | 
| Research Funding - Bristol-Myers Squibb; MSD; Novartis; Pfizer | 
|  | 
|  | 
| Honoraria - Bristol-Myers Squibb; Incyte; Merck; Novartis; Roche | 
| Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; Pierre Fabre; Roche/Genentech | 
|  | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Amgen; Novartis | 
|  | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Novartis | 
|  | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Novartis | 
| Travel, Accommodations, Expenses - Novartis | 
|  | 
|  | 
| Employment - GlaxoSmithKline; Novartis | 
| Stock and Other Ownership Interests  - AstraZeneca; GlaxoSmithKline; Incyte; Novartis | 
|  | 
|  | 
| Honoraria - Bristol-Myers Squibb; MSD; Novartis | 
| Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre | 
| Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Roche | 
| Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |